Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

F. Sora, A. Iurlo, S. Sica, R. Latagliata, M. Annunziata, S. Galimberti, F. Castagnetti, P. Pregno, N. Sgherza, F. Celesti, M. Bocchia, A. Gozzini, C. Fava, D. Cattaneo, M. Crugnola, E. Montefusco, E. Mauro, I. Capodanno, M. Breccia

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)267-270
Number of pages4
JournalBritish Journal of Haematology
Volume181
Issue number2
DOIs
Publication statusPublished - 2018

Keywords

  • dasatinib
  • hydroxyurea
  • imatinib
  • nilotinib, activated partial thromboplastin time
  • adult
  • aged
  • bleeding
  • cancer chemotherapy
  • cancer survival
  • chronic myeloid leukemia
  • clinical feature
  • drug effect
  • female
  • human
  • human tissue
  • iron deficiency
  • Letter
  • major clinical study
  • male
  • outcome assessment
  • overall survival
  • platelet count
  • priority journal
  • risk reduction
  • survival time
  • thrombocytopheresis
  • thrombocytosis
  • treatment planning

Cite this

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. / Sora, F.; Iurlo, A.; Sica, S.; Latagliata, R.; Annunziata, M.; Galimberti, S.; Castagnetti, F.; Pregno, P.; Sgherza, N.; Celesti, F.; Bocchia, M.; Gozzini, A.; Fava, C.; Cattaneo, D.; Crugnola, M.; Montefusco, E.; Mauro, E.; Capodanno, I.; Breccia, M.

In: British Journal of Haematology, Vol. 181, No. 2, 2018, p. 267-270.

Research output: Contribution to journalArticle

Sora, F, Iurlo, A, Sica, S, Latagliata, R, Annunziata, M, Galimberti, S, Castagnetti, F, Pregno, P, Sgherza, N, Celesti, F, Bocchia, M, Gozzini, A, Fava, C, Cattaneo, D, Crugnola, M, Montefusco, E, Mauro, E, Capodanno, I & Breccia, M 2018, 'Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome', British Journal of Haematology, vol. 181, no. 2, pp. 267-270. https://doi.org/10.1111/bjh.14553
Sora, F. ; Iurlo, A. ; Sica, S. ; Latagliata, R. ; Annunziata, M. ; Galimberti, S. ; Castagnetti, F. ; Pregno, P. ; Sgherza, N. ; Celesti, F. ; Bocchia, M. ; Gozzini, A. ; Fava, C. ; Cattaneo, D. ; Crugnola, M. ; Montefusco, E. ; Mauro, E. ; Capodanno, I. ; Breccia, M. / Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. In: British Journal of Haematology. 2018 ; Vol. 181, No. 2. pp. 267-270.
@article{009dba66bc51463aa506b2a8141e583b,
title = "Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome",
keywords = "dasatinib, hydroxyurea, imatinib, nilotinib, activated partial thromboplastin time, adult, aged, bleeding, cancer chemotherapy, cancer survival, chronic myeloid leukemia, clinical feature, drug effect, female, human, human tissue, iron deficiency, Letter, major clinical study, male, outcome assessment, overall survival, platelet count, priority journal, risk reduction, survival time, thrombocytopheresis, thrombocytosis, treatment planning",
author = "F. Sora and A. Iurlo and S. Sica and R. Latagliata and M. Annunziata and S. Galimberti and F. Castagnetti and P. Pregno and N. Sgherza and F. Celesti and M. Bocchia and A. Gozzini and C. Fava and D. Cattaneo and M. Crugnola and E. Montefusco and E. Mauro and I. Capodanno and M. Breccia",
note = "cited By 1",
year = "2018",
doi = "10.1111/bjh.14553",
language = "English",
volume = "181",
pages = "267--270",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

AU - Sora, F.

AU - Iurlo, A.

AU - Sica, S.

AU - Latagliata, R.

AU - Annunziata, M.

AU - Galimberti, S.

AU - Castagnetti, F.

AU - Pregno, P.

AU - Sgherza, N.

AU - Celesti, F.

AU - Bocchia, M.

AU - Gozzini, A.

AU - Fava, C.

AU - Cattaneo, D.

AU - Crugnola, M.

AU - Montefusco, E.

AU - Mauro, E.

AU - Capodanno, I.

AU - Breccia, M.

N1 - cited By 1

PY - 2018

Y1 - 2018

KW - dasatinib

KW - hydroxyurea

KW - imatinib

KW - nilotinib, activated partial thromboplastin time

KW - adult

KW - aged

KW - bleeding

KW - cancer chemotherapy

KW - cancer survival

KW - chronic myeloid leukemia

KW - clinical feature

KW - drug effect

KW - female

KW - human

KW - human tissue

KW - iron deficiency

KW - Letter

KW - major clinical study

KW - male

KW - outcome assessment

KW - overall survival

KW - platelet count

KW - priority journal

KW - risk reduction

KW - survival time

KW - thrombocytopheresis

KW - thrombocytosis

KW - treatment planning

U2 - 10.1111/bjh.14553

DO - 10.1111/bjh.14553

M3 - Article

VL - 181

SP - 267

EP - 270

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -